



The Erganoid-1™

Improving cancer treatments

Contacts:
Swiss Medical Union SA
CH-550.1.183.498-2

c/o Y-Parc SA
Rue Galilée 7 - 1400 Yverdon-les-Bains

Prepared for the

Seedstars – Investor Forum in Phnôm Pênh

28 November 2019

Daniil Golubev (CEO)

Marion Argi (CMO)

Emanuele Pizzatti (CFO)



The effectiveness of cancer treatment depends on many factors, such as the **time gap** between diagnosis and start of treatment. These data are collected by all registries. The effectiveness of treatment also depends on the **type** of treatment as well as the **multidisciplinary** care of the patient; the impact of which is more **difficult to quantify**

Three interconnected major problems

Time to treatment

Slow process and waiting time negatively impacts the **success rate** of the treatments as **complications** arises.

Negative side effects & complications

Palliative (comfort) and generalized solutions as part primary cancer treatments are often used to gain time.

Increasing costs on the healthcare


Costs raises with **trial & error** approach not only leads to invasive treatments and higher healthcare expenditures.

Moreover, it costs LIVES as cancer survival rate is 50%

Impacts on the **healthcare sector**


Service provision

- It is currently ineffective due to operational inefficiencies
- It generates **collateral expenditures** as palliative treatments are used to gain time
- Treatments are often ineffective due to **lack of patient data** which lead to wrong medical decisions
- Current treatment and diagnostics are expensive and **no inclusive** as pricing point do not enable the universal supply – insurance companies struggle to pay less.



The Solution: Erganoid - 1™

Ex-vivo testing of real patient samples with several proposed treatments. Optimal treatment can be identified within 7 days, without harming the patient unnecessarily.




Quick and individual treatment

Erganoid – 1™ is a human’s organ *biochip* specifically designed to increase the accuracy in treatment selection for patient in intensive care.

Such will be done without injecting any drugs into the patient on a “trial-and-error” basis and without testing products on animals.

Technical Profile: Erganoid - 1™





Over
100
tests
have
been
made

+65%


Survival rate score – of cells
multiplication success rate

70 to 75%

Success rate –
of reaction to treatment





*More opportunities to test different treatment models and track
their outcome*



Improved treatment Sensitivity and Specificity

Business model: clinical practice inclusion and R&D Labs


Clinics & Research
Laboratories



Micro-Bioreactor
CHF 25'000

Device

One-off payment



Bio-chip
CHF 400

Consumables

Recurring revenue



Customer support
& Training

Pay-as-you-go

Recurring revenue



Ad-hoc service &
SW customization
for labs

**Individual
solutions**

Hourly Fees

Our Team, business advisors and partners



Daniil Golubev – CEO & Founder
Public health professional, Academic
researcher for HUG, CH



Marion Argi – CMO
PR & Communication specialist



Andrey Alikimovich – CTO
Web technologies specialist



Emanuele Pizzatti – CFO
Venture Partner, startup coach &
advisor



Strategic partner for testing & product validation

initiating research of partners for production

Advisory Board

Dr. Dmitry Skorchelletti - Business Expert,
Expert for Roszdravnadzor, FDA Russia

Patrick Debergh - Senior patent Engineer
specialised in Microsystems, Micro-nano
technologies and micro-optics IP

Dr. Ivan Tretyakov - Business Expert Legal
expert in international expansion

Scientific Board

Prof. Alexander Tonevitsky - Inventor of the
technology, Program Head of the Cellular &
Molecular Biotechnologies at the HSE
University, Moscow

Prof. Dr. Med. Udo Schumacher - Director of
of Anatomy and Experimental Morphology,
University Medical Center Hamburg –
Eppendorf, Germany

Prof. Idris Guessous - Head of Population
Epidemiology, HUG/ CH

You should not miss this investment because

We can satisfy a large market need. With the «Man-on-the-Chip» technology, we end «Trial & Error» testing for very sick patients

Our product has a clear short-term development path. Ready for take-off mid 2020 – including international patent.

Investment will pay-back within short time. Profitable business with exit possible 2024 once Micro-Bioreactor is developed (or earlier TBD).

Contacts:

Swiss Medical Union Sarl
CH-550.1.183.498-2

c/o Y-Parc SA
Rue Galilée 7 - 1400 Yverdon-les-Bains
CH-550.1.183.498-2

Danil Golubev

+41 79 630 61 49
dgolubev@medicalunion.swiss

Emanuele Pizzatti

+41 78 924 03 84
epizzatti@medicalunion.swiss

THANK YOU!